News

If approved, Arzerra (ofatumumab) would be indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have previously failed, or are inappropriate for, standard therapies. Ofatumumab

In his most recent endeavor, he served as chief executive officer (CEO) of Living Cell Technologies. He was earlier president and CEO of Aurogen, a privately held biotech

For the fourth quarter period, revenues were $20.8 million, against $19.7 million from the prior-year period. The company recorded operating income of $1.1 million for the three-month period,

GAAP net income rose to $86.7 million, or $0.31 per diluted share, compared with $78.9 million, or $0.29 per diluted share, in the prior fourth quarter. Non-GAAP net

This products suite includes MammaPrint, the only FDA approved test for rapidly and accurately diagnosing therapeutic options for breast cancer patients. Additionally, he will play an important role

“This past year was pivotal for Sequenom as we continued to advance our genetic analysis and molecular diagnostics businesses,” stated Harry Stylli, president and chief executive officer of

As a result of the court’s decision, Par will accrue additional reserves of approximately $28 million on an after-tax basis in the fourth quarter of 2008. Par and

As part of the transaction, Allscripts intends to continue to offer medication services to existing and future clients of Allscripts under a co-marketing agreement. Closing of the transaction

According to QuantRx, this new patent for oral testing devices expands the company’s protection, and will allow it to bring its ultrasensitive RapidSense technology to address the point-of-care